Loomis, Sayles & Company’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $670M | Sell |
1,363,758
-14,711
| -1% | -$7.98M | 0.9% | 25 |
|
|
2025
Q4 | $799M | Sell |
1,378,469
-34,214
| -2% | -$19.3M | 0.96% | 22 |
|
|
2025
Q3 | $685M | Sell |
1,412,683
-1,709
| -0.1% | -$795K | 0.82% | 26 |
|
|
2025
Q2 | $573M | Buy |
1,414,392
+67,412
| +5% | +$28.2M | 0.72% | 28 |
|
|
2025
Q1 | $670M | Buy |
1,346,980
+93,627
| +7% | +$50.7M | 0.97% | 25 |
|
|
2024
Q4 | $652M | Sell |
1,253,353
-44,659
| -3% | -$24.6M | 0.82% | 25 |
|
|
2024
Q3 | $803M | Sell |
1,298,012
-24,151
| -2% | -$14.3M | 1.05% | 22 |
|
|
2024
Q2 | $731M | Buy |
1,322,163
+165,144
| +14% | +$94.6M | 1.01% | 24 |
|
|
2024
Q1 | $672M | Buy |
1,157,019
+1,705
| +0.1% | +$957K | 0.96% | 27 |
|
|
2023
Q4 | $613M | Buy |
1,155,314
+181,723
| +19% | +$88M | 0.94% | 28 |
|
|
2023
Q3 | $493M | Buy |
973,591
+967,913
| +17,047% | +$516M | 0.85% | 29 |
|
|
2023
Q2 | $2.96M | Sell |
5,678
-395
| -7% | -$213K | ﹤0.01% | 427 |
|
|
2023
Q1 | $3.5M | Buy |
6,073
+149
| +3% | +$84K | 0.01% | 418 |
|
|
2022
Q4 | $3.26M | Buy |
5,924
+1,944
| +49% | +$1.03M | 0.01% | 399 |
|
|
2022
Q3 | $2.02M | Sell |
3,980
-13,407
| -77% | -$7.5M | ﹤0.01% | 406 |
|
|
2022
Q2 | $9.45M | Sell |
17,387
-2,457
| -12% | -$1.35M | 0.02% | 358 |
|
|
2022
Q1 | $11.7M | Buy |
19,844
+16,853
| +563% | +$9.68M | 0.02% | 354 |
|
|
2021
Q4 | $2M | Sell |
2,991
-580
| -16% | -$362K | ﹤0.01% | 452 |
|
|
2021
Q3 | $2.04M | Sell |
3,571
-389
| -10% | -$214K | ﹤0.01% | 449 |
|
|
2021
Q2 | $2M | Buy |
3,960
+389
| +11% | +$184K | ﹤0.01% | 444 |
|
|
2021
Q1 | $1.63M | Buy |
3,571
+250
| +8% | +$119K | ﹤0.01% | 462 |
|
|
2020
Q4 | $1.55M | Buy |
3,321
+2,732
| +464% | +$1.28M | ﹤0.01% | 455 |
|
|
2020
Q3 | $260K | Buy |
589
+447
| +315% | +$185K | ﹤0.01% | 497 |
|
|
2020
Q2 | $51K | Sell |
142
-7
| -5% | -$2.35K | ﹤0.01% | 545 |
|
|
2020
Q1 | $42K | Sell |
149
-522
| -78% | -$165K | ﹤0.01% | 561 |
|
|
2019
Q4 | $218K | Buy |
671
+60
| +10% | +$18.2K | ﹤0.01% | 524 |
|
|
2019
Q3 | $178K | Sell |
611
-13,590
| -96% | -$3.89M | ﹤0.01% | 519 |
|
|
2019
Q2 | $4.17M | Sell |
14,201
-3,388
| -19% | -$933K | 0.01% | 437 |
|
|
2019
Q1 | $4.81M | Buy |
17,589
+7,956
| +83% | +$1.98M | 0.01% | 439 |
|
|
2018
Q4 | $2.16M | Buy |
9,633
+9,578
| +17,415% | +$2.25M | 0.01% | 502 |
|
|
2018
Q3 | $13K | Buy |
+55
| New | +$12.7K | ﹤0.01% | 783 |
|
|
2017
Q4 | – | Sell |
-132
| Closed | -$25K | – | 934 |
|
|
2017
Q3 | $25K | Sell |
132
-5
| -4% | -$906 | ﹤0.01% | 730 |
|
|
2017
Q2 | $24K | Buy |
+137
| New | +$23K | ﹤0.01% | 746 |
|
|
2016
Q4 | – | Sell |
-3
| Closed | – | – | 1103 |
|
|
2016
Q3 | $0 | Buy |
+3
| New | +$462 | ﹤0.01% | 1069 |
|
|
2015
Q4 | – | Sell |
-42
| Closed | -$5K | – | 1114 |
|
|
2015
Q3 | $5K | Buy |
+42
| New | +$5.47K | ﹤0.01% | 950 |
|
|
2014
Q3 | – | Sell |
-253,653
| Closed | -$29.9M | – | 749 |
|
|
2014
Q2 | $29.9M | Sell |
253,653
-34,689
| -12% | -$4.08M | 0.09% | 222 |
|
|
2014
Q1 | $34.7M | Buy |
288,342
+94,920
| +49% | +$11.3M | 0.1% | 201 |
|
|
2013
Q4 | $21.5M | Sell |
193,422
-85,308
| -31% | -$8.48M | 0.06% | 324 |
|
|
2013
Q3 | $25.7M | Buy |
278,730
+22,267
| +9% | +$2.01M | 0.08% | 243 |
|
|
2013
Q2 | $21.7K | Buy |
+256,463
| New | +$21.3M | 0.08% | 268 |
|
Other funds holding TMO
VCM
Loomis, Sayles & Company's TMO Position: Q1 2026 in Review
Loomis, Sayles & Company reduced its Thermo Fisher Scientific (TMO) stake by 1.1% in Q1 2026, selling an estimated $7.98M and leaving 1,363,758 shares worth $670M. The position accounts for 0.9% of the portfolio, ranked #25.
Loomis, Sayles & Company first reported a position in TMO in Q2 2013 and has held it in 40 quarters since. The position peaked at $803M in Q3 2024. 2,588 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Loomis, Sayles & Company held 1,363,758 shares of Thermo Fisher Scientific worth $670M as of Q1 2026.
- Loomis, Sayles & Company sold 14,711 Thermo Fisher Scientific shares in Q1 2026, an estimated $7.98M.
- Thermo Fisher Scientific made up 0.9% of Loomis, Sayles & Company's portfolio in Q1 2026, its #25 holding.
- Loomis, Sayles & Company first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 40 quarters since.
- Loomis, Sayles & Company's Thermo Fisher Scientific position peaked at $803M in Q3 2024.
- 2,588 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.